Heparin Monitoring and Anticoagulation Therapy

Heparin remains a cornerstone of anticoagulation therapy in diverse clinical settings, from intensive care units to cardiac surgery and thromboprophylaxis. Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) differ in molecular weight, pharmacokinetics and monitoring requirements. UFH’s effect is traditionally guided by the activated partial thromboplastin time (APTT), whereas LMWH is commonly dosed by fixed regimens and monitored via anti-factor Xa assays when necessary. Recent advances have highlighted interindividual variability in heparin response, driven by factors such as coagulation factor levels, antithrombin concentration and procedural variables. Contemporary research has focused on optimising assay accuracy, reducing turnaround times with point-of-care platforms and refining dosing nomograms through models that incorporate patient characteristics. The global significance of precise heparin monitoring extends to minimising bleeding and thrombotic complications, improving safety in vulnerable populations and informing personalised anticoagulation strategies.

Research from Nature Portfolio

Individual variation in unfractionated heparin dosing after paediatric cardiac surgery has been quantified in a study of children undergoing procedures such as Blalock-Taussig shunts, Glenn and Fontan operations. Analysis of clinical and biochemical variables revealed that type of surgery explained only around 30% of the variance in heparin infusion rates, leaving the majority of dosing variability unaccounted for. These findings underscore the limitations of weight-based nomograms and point to a need for novel biomarkers or pharmacogenetic profiling to guide initial dosing and maintenance infusions in complex paediatric cohorts.

Heparin Monitoring and Anticoagulation Therapy publication trend

The graph below shows the total number of articles in heparin monitoring and anticoagulation therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Unfractionated heparin (UFH): A heterogeneous mixture of glycosaminoglycan chains used intravenously or subcutaneously with an unpredictable dose–response relationship.

Low molecular weight heparin (LMWH): Fragments of UFH with more consistent bioavailability and longer half-life, often given by fixed dosing.

Activated partial thromboplastin time (APTT): A global clotting assay measuring the intrinsic and common coagulation pathways to adjust UFH dosing.

Anti-factor Xa assay: A chromogenic assay quantifying inhibition of factor Xa by heparin, providing a direct measure of anticoagulant concentration.

Point-of-care testing: Rapid assays performed at or near the bedside to deliver timely anticoagulation results and guide immediate dose adjustments.

References

1. Individual variation in unfractionated heparin dosing after pediatric cardiac surgery. Scientific Reports (2020).
2. Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study. Journal of Intensive Care (2023).
3. Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement. Journal of Clinical Medicine (2022).
4. Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity. Biomedicines (2021).
5. Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes. Thrombosis Journal (2023).